OncoHost to Present New PROphetNSCLC® Data at WCLC 2026 Demonstrating Predictive Performance Beyond Baseline Sampling

New findings support the applicability of PROphetNSCLC® following chemo or immunotherapy-based cycle, potentially broadening its real-world clinical utility

BINYAMINA, Israel and CARY, N.C., Sept. 10, 2026 /PRNewswire/ -- OncoHost, a technology company transforming precision oncology through proteomics-based biomarker development, today announced its acceptance to present a scientific poster at the 2026 World Conference on Lung Cancer (WCLC), taking place September 12–15, 2026, in Seoul, South Korea.

The poster, titled "PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC," evaluates whether PROphetNSCLC® maintains its predictive performance when blood samples are collected beyond the traditional pre-treatment time point.

PROphetNSCLC® is a plasma proteomics-based test designed to guide immune checkpoint inhibitor (ICI) treatment decision-making in advanced non-small cell lung cancer (NSCLC). While PROphetNSCLC® was developed using samples collected prior to initiation of ICI treatment, real-world clinical workflows may not always allow for baseline blood collection. The study therefore assessed the stability of the plasma proteome and the concordance of PROphetNSCLC® result in different sampling time points.

"The PROphet plasma proteomic assay has proven clinical utility as a baseline in treatment naïve patients, but in practice some patients don't have pre-treatment samples" said Dr. David Gandara, Medical Oncologist & clinical-translational researcher in lung cancer, Co-Director-Center for Experimental Therapeutics, UC Davis Comprehensive Cancer Center, Clinical Advisor at OncoHost and co-author of the study. "These new data that PROphet results remain stable even after a patient begins chemotherapy or immunotherapy reinforce the reliability and clinical applicability of the assay".

"Immunotherapy is today the cornerstone of treatment for NSCLC patients without an oncogenic driving abnormality", added Fred Hirsch, MD, PhD, FASCO, Professor of Medicine & Pathology, Medical Oncologist, Clinical Advisor at OncoHost and co-author of the study. "The PROphet blood-based assay has demonstrated in several studies it can predict which patients who will benefit from immunotherapy with or without chemotherapy or not. The presented study shows the predictive stability of the test even if it is sampled during treatment, which makes the test very usable in the real-world setting".

The analysis included plasma samples collected from patients with advanced NSCLC receiving ICI-based therapies at three time points: prior to treatment; following one cycle of chemotherapy but before initiation of ICI therapy; and following one cycle of ICI-based treatment. Proteomic profiling measured 7,289 proteins, while investigators evaluated changes across the plasma proteome, preservation of Resistance Associated Protein (RAP; the PROphetNSCLC® model proteins) expression, and the consistency of PROphet® classification.

Results demonstrated substantial preservation of the biological signal underlying PROphetNSCLC® despite treatment initiation. Among matched samples collected at baseline and following one cycle of chemotherapy, only 20 of the 7,289 measured proteins were differentially expressed, with none belonging to the 388 RAPs used by PROphet®. Greater proteomic changes were observed following one cycle of ICI-based treatment, with 888 differentially expressed proteins, including 81 RAPs. Despite these changes, more than 73% of RAPs remained strongly correlated between matched samples across both longitudinal comparisons.

Comparison between the plasma proteome at baseline and after 1 chemotherapy or ICI-based cycle showed that more than 73% of the RAPs remained strongly correlated between matched samples. In concordance with the RAP preservation, PROphet® classification demonstrated high consistency between matched samples, reaching 80% following chemotherapy and 69% following one cycle of ICI-based treatment, with no significant systematic bias compared with baseline classification. Importantly, PROphet® maintained significant separation in overall survival between PROphet-POSITIVE and PROphet-NEGATIVE patients following one cycle of ICI-based treatment (HR=0.54, p=0.009).

"These findings represent an important step in expanding the real-world clinical utility of PROphetNSCLC®," said Ofer Sharon, M.D., CEO of OncoHost. "Our goal is to ensure that more patients can benefit from precision treatment guidance, even when the realities of clinical care may require treatment to begin before all biomarker results are available. Demonstrating that PROphet® maintains its predictive performance following one cycle of chemotherapy broadens the patient population for whom the test may be relevant and reinforces our commitment to delivering precision oncology solutions that integrate seamlessly into real-world clinical practice."

Poster Presentation Details
Title: PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC
Poster Board #: P2.188
Presenters: David R. Gandara, M.D. & Fred Hirsch, M.D., co-authors of the study
Date & Time: 14/09/26 10:30-12:00 PM KST.

About OncoHost
OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina, transforming the approach to precision medicine for improved patient outcomes. OncoHost's proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC® test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival.

Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, X (Twitter), Facebook, and YouTube.

Media Contact:

Mimi Strahl – Ben Simon

Marcom Manager, OncoHost  
[email protected]

+972-50-428-1138

SOURCE OncoHost